In terms of Covid-19, the US Surgeon General said this week is going to get BAD.
The following thought occurred to me, which applies not just to ADXS, but to all bios running clinical trials.
As Covid-19 sweeps through the world and the nation, there is the real possibility of patient populations in clinical trials being decimated.
I think there is an increased probability of mortality for those with underlying conditions enrolled in trials, resulting in delays and skewed data. Determining the exact root cause of such an adverse event, will be an extremely delicate and complicated matter. And to add to the misery, think of the risk of an FDA hold on a particular trial, if not an entire pipeline.
The risk in biotech clinical trials is unprecedented and unlike anything in our lifetimes, IMO.
Just sayin.
(Feel free to share my thought with others who may be heavily invested in lightly funded bios, so they can weigh this risk).
JMHO
News 
Market Data 
Discover 
